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Summary 23 
T follicular helper (TFH) and Cytotoxic CD4 (ThCTL) are tissue-restricted CD4 effector subsets, 24 
functionally specialized to mediate optimal Ab production and cytotoxicity of infected cells. 25 
Influenza infection generates robust CD4 responses, including lung ThCTL and SLO TFH, that 26 
protect against reinfection by variant strains. Antigen (Ag) presentation after infection, lasts 27 
through the effector phase of the response. Here, we show that this effector phase Ag presentation, 28 
well after priming, is required to drive CD4 effectors to ThCTL and TFH. Using in vivo influenza 29 
models, we varied Ag presentation to effectors acutely, just at the effector phase. Ag presentation 30 
was required in the tissue of effector residence. We suggest these requirements contain 31 
unnecessary or potentially pathogenic CD4 responses, only allowing them if infection is uncleared. 32 
The results imply that providing effector phase Ag, would lead to stronger humoral and CD4 tissue 33 
immunity and thus can be applied to improve vaccine design.  34 
 35 
 36 
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INTRODUCTION 44 
A key challenge for the immune system is to respond strongly against dangerous pathogens, while 45 
limiting response to non-threatening foreign antigens, so as to limit immunopathology. Naïve CD4 46 
T cells achieve this discrimination by requiring three signals during priming at the beginning of 47 
the response to generate the initial effector populations: high levels of antigen (Ag), co-stimulation 48 
and inflammatory cytokines (Dubey and Croft, 1996). These effectors defend the body against 49 
foreign Ag during the effector phase and finally contract after the Ag has waned to become long 50 
lived memory T cells. A cohort of the CD4 effectors can differentiate further, to become tissue-51 
restricted effectors, including T follicular helpers (TFH)  (Fazilleau et al., 2009; Lee et al., 2015) 52 
and cytotoxic CD4 T cells (ThCTL) (Marshall et al., 2016).  53 
TFH are tissue-restricted CD4 effectors in the secondary lymphoid organs such as the spleen and 54 
lymph nodes (Fazilleau et al., 2009; Lee et al., 2015). They drive the germinal center reaction and 55 
the resulting antibody (Ab) responses during the immune response (Crotty, 2019). ThCTL are 56 
cytotoxic CD4 effectors that target cells expressing MHC-II, which may also have downregulated 57 
MHC-I due to evasion mechanisms, and play important roles in controlling viral infections and 58 
tumors (Juno et al., 2017; Koutsakos et al., 2019a; Marshall and Swain, 2011; Marshall et al., 59 
2016; Muraro et al., 2017; Phetsouphanh et al., 2017). Previously, we showed that ThCTL induced 60 
by viral infections are resident in the infected tissue (Marshall et al., 2016). During influenza virus 61 
infection, ThCTL arise 7 days post infection (dpi) in lungs of infected mice. ThCTL express 62 
NKG2C/E, which reliably marks the CD4 effector subset with MHC-II restricted cytotoxicity. 63 
Both TFH and ThCTL are also upregulated in various human autoimmune diseases (Broadley et 64 
al., 2017; Gensous et al., 2018). Despite their important roles in autoimmune disease, infection, 65 
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and cancer, little is known about the signals that regulate the transition of early CD4 effectors into 66 
these later tissue effectors.  67 
Our current understanding of CD4 tissue-restricted effectors is largely inferred from studies of TFH 68 
during T:B interaction in responding germinal centers. Over the past decade we have learned that 69 
after priming, TFH repeatedly interact with B cells in germinal centers to support GC responses. 70 
The germinal center B cells (GCB) reciprocally support TFH differentiation, survival and expansion 71 
(Vinuesa et al., 2016). Studies have shown that TFH generation is enhanced by repeated 72 
immunization (Baumjohann et al., 2013; Deenick et al., 2010; Tam et al., 2016), but it is unclear 73 
if Ag is required both for initial priming and at the effector phase. CD4 effectors generated during 74 
LCMV infection,  depended on ongoing infection to effectively generate  TFH (Baumjohann et al., 75 
2013). In this study it was unclear whether Ag, or infection-generated inflammation, or both, were 76 
required to support TFH generation during the effector phase and if Ag presentation needed to occur 77 
in particular locations. While we know that TFH continuously interact with GCB that present Ag 78 
in situ, we do not know which aspects of this interaction are required during the effector phase, to 79 
regulate the development of CD4 tissue effector subsets.  Moreover, we do not know if the GC 80 
presents a niche, unique in its ability to fulfill requirements for CD4 tissue effector differentiation 81 
or if there are other signals that are able to substitute for them. An immunization study indicated 82 
that GCB depletion during the effector phase reduced TFH generation (Baumjohann et al., 2013). 83 
Another study showed that early TFH generation can occur independently of unique B cell signaling 84 
(Deenick et al., 2011), supporting the concept that when other APC presenting Ag are available, 85 
TFH may be able to develop by GCB independent pathways even during the effector phase, though 86 
this is unknown. Moreover, other CD4 tissue effectors such as ThCTL are not present in GC and 87 
we have little understanding of their development from early CD4 effectors, or if they have shared 88 
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or unique requirements with TFH.  Thus, while the GC studies give us many important clues about 89 
CD4 tissue effectors, they leave many questions unanswered. To fill these gaps, here we analyze 90 
the overall requirements for different aspects of Ag encounter, specifically during the CD4 effector 91 
phase well after priming, that drive CD4 effectors to become tissue-restricted effectors. 92 
We previously showed that CD4 effectors generated by influenza virus infection need to recognize 93 
Ag during the effector phase, 6-8 dpi, to effectively form long-lived memory (Bautista et al., 2016; 94 
McKinstry et al., 2014). Here, we ask if late steps in generation of TFH and ThCTL tissue effector 95 
subsets, also require cognate Ag recognition at this “effector checkpoint”. We reason that if an 96 
infection is quickly cleared or initial Ag is non-replicating, presentation of Ag will wane. Thus, 97 
such a checkpoint could act to limit further response when the infection (the source of Ag) is 98 
cleared, serving as a mechanism to prevent immunopathology and potential autoimmunity when 99 
there is no longer danger from a live pathogen.  100 
Here, we find that CD4 effectors must recognize cognate Ag during the effector checkpoint to 101 
become full-fledged ThCTL and TFH, and that multiple APC can support this transition. Moreover, 102 
for full development of DLN TFH, spleen TFH and lung ThCTL, effectors must recognize Ag 103 
presented at the site of tissue effector residency. CD28 co-stimulation during the effector 104 
checkpoint is required for TFH, but not for ThCTL generation. Thus, at the effector phase, well 105 
after Ag priming, multiple signals during cognate Ag recognition act in concert to drive different 106 
specialized CD4 fates: ThCTL, TFH and CD4 memory. This suggests that this effector CD4 107 
checkpoint regulates the quality, quantity and localization of CD4 tissue-restricted effectors and 108 
the memory cells they become. We discuss the relevance of these findings to designing vaccine 109 
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strategies that could induce effective long-lived Ab and cellular immunity against conserved 110 
epitopes. 111 
RESULTS 112 
Cognate Ag recognition at the CD4 effector checkpoint drives the generation of ThCTL 113 
phenotype and function in the lung  114 
We use a sequential transfer model, in which 6 dpi CD4 effectors are generated in vivo by 115 
transferring naïve HNT (specific for influenza A virus hemagglutinin) or OT-II (specific for an 116 
OVA epitope) Thy1.1 CD4 T cells, into primary hosts infected with PR8 or with PR8-OVAII 117 
influenza virus respectively (for 6 days). We then isolate the in vivo generated effectors and 118 
transfer them into 2nd hosts. The 2nd hosts are IAV infection-matched mice, i.e. also at 6 dpi when 119 
6 dpi effectors are transferred into them, to make the model physiologically relevant. In the 2nd 120 
hosts, we can independently modulate Ag availability by using Ag-pulsed APC (Ag/APC) 121 
transfers or virus infections. This allows us to clearly follow donor cell fate to ask specific 122 
questions about cognate Ag/APC interactions during the effector phase.  123 
In all experiments using the sequential transfer model, we analyze the transferred donor effector 124 
cells 2-4 days post transfer (8-10 days post infection) and not later, because ThCTL and TFH peak 125 
7-10 days post infection  (Marshall et al., 2016) (Fig S1D-E), and then effectors begin to contract 126 
after 10 dpi (Botta et al., 2017; Marshall et al., 2016).  Signals required for CD4 T cell priming 127 
during the first few days are well-defined (Swain et al., 2012). The sequential transfer model allows 128 
us to define signals required during the effector phase, well after priming, but before contraction. 129 
Since there is robust generation of both ThCTL and TFH during an in vivo influenza infection 130 
(Figure S1D-E), they serve as positive controls. Thus an important advantage of this TCR Tg 131 
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approach is that we can isolate 6d CD4 effectors generated by in vivo influenza infection, then 132 
transfer them with added/subtracted signals related to Ag into the 2nd infection matched hosts and 133 
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We first analyzed if early ThCTL had recently recognized Ag during an in vivo influenza infection. 151 
For this, we used influenza-specific TCR transgenic CD4 T (OT-II specific for PR8-OVAII) mice 152 
crossed to the Nur77GFP reporter mice, as a source of reporter CD4 T cells, to track recent TCR 153 
stimulation.  Nur77GFP cells transiently express Nur77GFP when they are  stimulated by Ag 154 
recognition (Au-Yeung et al., 2014; Bautista et al., 2016; Moran et al., 2011). Naïve OT-155 
II.Nur77GFP.Thy1.1+ CD4 T cells were transferred into wild-type (WT) hosts infected with PR8-156 
OVAII. NKG2A/C/E expression, identifying donor ThCTL in the lung (Marshall et al., 2016), was 157 
higher in the Nur77GFP+ subset at 6 dpi compared to the Nur77GFP- subset (Fig S1A), indicating 158 
they have recently recognized Ag.  159 
We used the sequential transfer approach (Bautista et al., 2016) to determine if 6 dpi effectors 160 
require Ag to become ThCTL (Figure 1A). We transferred naïve OT-II cells into hosts that were 161 
then infected with PR8-OVAII (1
st hosts). We isolated in vivo-generated OT-II effectors at 6 dpi. 162 
These were transferred into 2nd hosts that had been infected 6d previously (infection-matched). 163 
The 2nd hosts provided either Ag and infection (PR8-OVAII infection), infection without Ag (PR8 164 
infection) or neither (uninfected) (Figure 1A). Donor ThCTL generation was assessed 2 days post 165 
transfer (dpt) in the lung which corresponded to 8 days post infection. Donor ThCTL developed 166 
when Ag was presented in the 2nd hosts as expected (positive control), but their number was 167 
drastically reduced when Ag was absent (7x) (Figure 1B). The Ag-dependence was selective for 168 
ThCTL, as the total number of donor lung effectors was only reduced 1.7x (Fig S2A). Donor 169 
expression of indicators of cytotoxicity, that also characterize ThCTL, such as Granzyme B 170 
(GzmB) (Figure 1C) and the degranulation marker CD107a (Figure 1D), also depended on Ag 171 
presented in the 2nd host. Expression of other ThCTL-associated markers (Marshall et al., 2016) 172 
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by the donor lung effectors: PD1, CXCR6 and SLAM, were also Ag dependent, but active PSGL1 173 
and CXCR3 were not (Figure S2B-F). 174 
To assess in vivo cytotoxic function, the in vivo-generated effectors were transferred into 2nd hosts 175 
with or without Ag (as in Figure 1A) and additionally with CFSE-labeled target cells (Figure 1E). 176 
We found over 20% cytotoxicity (Ag-specific) in PR8-OVAII-infected hosts, but little cytotoxicity 177 
in PR8-infected hosts. Thus, donor cell mediated CD4 cytotoxicity only developed when effectors 178 
were exposed to Ag, correlating with percentage and number of ThCTL in Figure 1B.  179 
We also analyzed secretion of canonical Th1 effector cytokines such as IFNγ and TNFα by donor 180 
cells. In contrast to ThCTL that depend on Ag, the donor effectors recovered did not require Ag 181 
recognition to maintain the ability to secrete IFNγ and in fact TNFα secretion was lost when 182 
cognate Ag was present during the effector checkpoint (Figure 1F-G, Figure S2G).  Thus, a 183 
program leading to induction of ThCTL phenotypes and functions, but not general Th1 184 
characteristics, were coordinately driven in 6d effectors by cognate Ag recognition. 185 
Cognate Ag recognition at the effector checkpoint drives generation of TFH, GC-TFH and 186 
GCB in spleen and DLN 187 
TFH, like ThCTL, peak at 7-8 dpi (Figure S1D) and express specialized tissue-restricted and 188 
functional programs (Fazilleau et al., 2009; Lee et al., 2015; Vinuesa et al., 2016).  In the same 189 
experiment as in Figure S1A, TFH (CXCR5
hiBcl6hi) were also enriched in the Nur77GFP+ population 190 
at 6 dpi in both the lung draining lymph nodes (DLN) and the spleen, indicating they had recently 191 
recognized Ag (Figure S1B-C). To test if 6d effectors require cognate Ag recognition to fully 192 
develop into TFH in the secondary lymphoid organs (SLO), we assessed TFH and more 193 
differentiated germinal center TFH (GC-TFH) using the sequential transfer system described in 194 
Figure 1A. In the PR8-OVAII infection-matched positive controls, a strong donor TFH response 195 
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developed, while in PR8 infected-matched hosts without cognate Ag, very few donor TFH were 196 



















.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted September 3, 2020. . https://doi.org/10.1101/2020.09.03.281998doi: bioRxiv preprint 
      11 
 
Moreover, while they developed well in hosts with Ag, no donor GC-TFH were generated without 215 
Ag (Figure 2B, Figure S3C-D). TFH/GC-TFH-associated molecules PD1 and ICOS were highly 216 
expressed by day 8 only when Ag was available (Figure 2C-D, Figure S3E-F), and were reduced 217 
in the absence of Ag. Thus, results from the same sequential transfer experiment (Figure 1A) 218 
showed that spleen and DLN TFH (Figure 2A-D, Fig S3C-F), like lung ThCTL (Figure 1B-D), 219 
required cognate Ag recognition during the effector phase. 220 
IL-21 promotes TFH differentiation and is also produced by TFH. It mediates TFH function during 221 
the GC response (Vinuesa et al., 2016).  Indeed, the proportion of donor effectors secreting IL-21 222 
was higher in 2nd hosts with Ag than in those without Ag (Figure 2E, Figure S3G). In contrast, the 223 
ability to maintain production of cytokines not directly associated with TFH, such as IFNγ and 224 
TNFα were not Ag-dependent (Figure 2F-G). This indicates a selective dependence of TFH-225 
associated programs, but not other effector functions, on Ag recognition during the effector 226 
checkpoint. 227 
To evaluate the impact of Ag recognition at the effector checkpoint, on TFH function of helping 228 
GCB formation, we developed an in vivo GCB assay (Figure 2H). Endogenous host GCB are 229 
undetectable from 2-6 dpi after influenza infection (Figure S3H) because TFH have not yet fully 230 
formed (Figure S1D). However, we reasoned that if functional TFH were available earlier, they 231 
should accelerate GCB formation. Therefore, we transferred in vivo generated 6d OT-II effectors 232 
into hosts infected 2d previously with either PR8 (no cognate Ag) or PR8-OVAII (cognate Ag 233 
available) and analyzed host GCB 4d after transfer (6 dpi). Thus, this model allowed us to study 234 
the acceleration of host GCB formation, during a timeframe (2-6 dpi) when their endogenous GCB 235 
formation was low. Transfer of 6d donor effectors into PR8-OVAII-infected mice, caused a 236 
significant increase in total GCB formation (Figure 2I) and HA+ GCB formation (Figure 2J) while 237 
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their transfer to PR8-infected hosts did not boost GCB formation over the negative controls which 238 
received no effectors. These results indicate that the critical TFH function of inducing GCB cells 239 
and thus protective Ab responses, requires cognate Ag during the effector phase. Therefore, 240 
effector phase recognition of Ag is needed to drive induction of the key defining phenotypic and 241 
functional aspects of both ThCTL and TFH programs, leading to their development in their 242 
respective niches.   243 
TFH but not ThCTL require CD28 co-stimulation at the effector checkpoint 244 
T cells express CD28, which interacts with CD80/86 on APC during cognate interaction, co-245 
stimulating IL-2 production and initiating proliferation (Watts, 2010). We analyzed whether 246 
ThCTL generation requires CD28:CD80/CD86 co-stimulation during the effector checkpoint. 6d 247 
in vivo effectors were transferred into WT or CD80/86 deficient PR8-OVAII infection-matched 248 
hosts (Figure 3A). The recovery of total donor effectors in the lung was decreased (Figure S4A), 249 
when hosts lacked costimulatory ligands, but the proportion of lung donor ThCTL was increased 250 
(Figure 3B). Donor ThCTL numbers were unchanged (Figure 3B), suggesting non-ThCTL were 251 
lost, while ThCTL were retained. The level of NKG2A/C/E expression on donor ThCTL was 252 
increased in CD80/86KO compared with WT (Figure S4B) hosts, suggesting that the 253 
differentiation of ThCTL improved without CD28:CD80/86 co-stimulation. Next, we cultured in 254 
vivo-generated 6d effectors for 2d in vitro with anti-CD3 vs anti-CD3 plus CD28, to mimic effector 255 
phase Ag exposure, with and without CD28 co-stimulation (Figure 3C). No ThCTL developed 256 
without anti-CD3 (Figure S4C-D), mimicking the in vivo requirement for cognate Ag during the 257 
effector phase, as shown in Figure 1.  258 
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ThCTL developed when effectors were stimulated by CD3 alone and adding CD28 co-stimulation 260 
inhibited ThCTL generation (Figure S4D). Cytotoxic function also depended on anti-CD3 261 
stimulation and was inhibited when CD28 co-stimulation was provided in vitro (Figure 3D). 262 
Together the in vitro and in vivo results indicate that ThCTL differentiation from 6d effectors does 263 
not require CD28 co-stimulation. The lack of a need for CD28 co-stimulation is also reminiscent 264 
of human ThCTL that studies have defined as CD28 negative populations (Serroukh et al., 2018; 265 
van de Berg et al., 2008). 266 
 In the same experiments (Figure 3A), both the proportion and absolute number of donor TFH and 267 
GC-TFH in the spleen and DLN were dramatically lower in the CD80/86 KO hosts (Figure 3E-F, 268 
Figure S4E-F). This agrees with previous data showing that CD28 co-stimulation post priming is 269 
necessary for TFH generation and maintenance (Linterman et al., 2014). Thus, CD28 co-stimulation 270 
of CD4 effectors at the effector checkpoint is required for full development of TFH in the spleen 271 
and the DLN but is not required to sustain or induce further ThCTL generation in the lung. This 272 
indicates that while both pathways of tissue-restricted effector development require Ag, the two 273 
have distinct co-stimulation requirements during the effector phase. This is consistent with a 274 
potential for multiple fate decisions taking place at this effector checkpoint, depending on the 275 
details of the cognate interactions.  276 
Multiple APC subsets can effectively present Ag at the effector checkpoint to drive TFH and 277 
ThCTL development 278 
We wondered if the distinct CD28 co-stimulation requirements for ThCTL and TFH subset 279 
development might reflect a requirement for distinct APC subsets. To evaluate the efficacy of 280 
different broad classes of APC at the effector checkpoint, we used MHC-II KO bone marrow 281 
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chimeras, CD11cTg.H2-Ab1−/− mice and JhD mice as 2nd hosts or provided Ag on distinct APC 282 
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We transferred 6d effectors into infection-matched BM chimeras in which MHC II Ag-302 
presentation was restricted to either the hematopoietic compartment [WT → MHC-II KO 303 
chimeras] (Figure 4B, Figure S5A) or to the non-hematopoietic compartment [MHC-II KO→ WT 304 
chimeras] (Figure 4C, Figure S5B). There was no defect in ThCTL generation when MHC-II was 305 
restricted to the hematopoietic compartment. A substantial ThCTL population was also generated 306 
when MHC-II was restricted to non-hematopoietic cells though we found significantly fewer donor 307 
ThCTL (Figure 4C).  Since a substantial ThCTL population was generated in both chimeras 308 
(Figure 4B-C, Figure S5A-B), it suggests that both hematopoietic and non-hematopoietic APC can 309 
present the Ag, to drive ThCTL development at the effector checkpoint. MHC-II is upregulated on 310 
infected epithelial cells in the lung during IAV infection, so they may be a source of non-311 
hematopoietic APC (Brown et al., 2012). Donor TFH were found when Ag was restricted to the 312 
hematopoietic compartment (Figure 4B, Figure S5A). In contrast, few if any TFH were found when 313 
Ag presentation was restricted to the non-hematopoietic compartment (Figure 4C, Figure S5B), 314 
consistent with few non-hematopoietic MHC-II+ cells presenting Ag in the SLO (Malhotra et al., 315 
2013).  316 
Since the hematopoietic compartment was sufficient to support Ag presentation to both TFH and 317 
ThCTL, we next asked if either of the classic APC: B cells and DCs, would be sufficient to drive 318 
the tissue-restricted effectors. We restricted Ag-presentation to CD11c+ APCs by using 319 
CD11cTg.H2-Ab1−/− mice (Figure 4D, Figure S5C). There was no defect in either donor ThCTL 320 
or TFH formation when 6d effectors were transferred into PR8-OVAII infection-matched mice with 321 
MHC-II only on CD11c+ APC, indicating that CD11c+ APC are sufficient to drive  both ThCTL 322 
and TFH during the effector checkpoint. 323 
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B cells are the major APC for TFH differentiation once they arrive in the follicular region of the 324 
SLO (Krishnaswamy et al., 2018). To test whether B cells were necessary as APC for driving 325 
tissue-restricted effectors during the effector checkpoint, we transferred in vivo generated 6d HNT 326 
Thy1.1 (TCR Tg specific for HA epitope of the influenza strain) effectors into PR8 infection-327 
matched B cell deficient JhD mice (Figure 4E, Figure S5D). Substantial numbers of ThCTL and 328 
TFH were generated in the B cell deficient JhD hosts, though in both cases there was a two-fold 329 
decrease in the number. This suggests that although B cell do contribute during the effector phase 330 
as APC, non-B cells can also serve as APC for both ThCTL and TFH pathways.  331 
 We evaluated the impact of providing Ag on two different professional APC subsets: DC (Figure 332 
4F, Figure S5E) and B cells (Figure 4G, Figure S5F). OVAII/APC were transferred together with 333 
in vivo generated 6d effectors into PR8 infection-matched mice. The 6d effectors gave rise to 334 
ThCTL and TFH when either B cells or DC presented Ag (Figure 4F-G, Figure S5E-F). We have 335 
established previously that the OVAII/DC present Ag for less than 2d in vivo (Bautista et al., 2016). 336 
The OVAII/DC transfer experiments suggest that, as for memory generation (Bautista et al., 2016), 337 
Ag recognition for the generation of TFH and ThCTL, is only required for less than 2d after effector 338 
transfer,  indicating a short window for Ag recognition and a temporally-defined checkpoint.  339 
Thus, multiple subsets of APC efficiently presented Ag to effectors to drive ThCTL formation 340 
including activated professional APC, such as DC and B cells, as well as non-hematopoietic cells 341 
in infected mice. TFH were generated in all experiments where hematopoietic MHC-II
+ 342 
presentation was available to the 6d effectors during the effector checkpoint. Thus, development 343 
of both CD4 tissue effectors during the effector phase, is independent of any unique APC type, 344 
with multiple APC able to be drive these fates. 345 
 346 
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Ag delivery to the lung during the effector phase selectively drives lung ThCTL generation 347 
We hypothesized that Ag recognition during the effector checkpoint might be required in the site 348 
of residence to drive tissue-restricted effectors and that this might act to establish residency. To 349 
evaluate this for ThCTL generation, we first tested whether intranasal (i.n.) delivery of Ag/APC 350 
could target Ag presentation to the lung. We also transferred Ag/APC intrasplenically (i.s.) to 351 
exclude Ag presentation in the lung.             352 
 353 
 354 
                        355 
We evaluated the localization of the APC using i.n. and i.s. delivery, and also evaluated 356 
corresponding Ag recognition by the transferred OT-II in the different sites (Table 1). To evaluate 357 
Ag recognition by effectors in the different sites using Nur77GFP expression, we transferred OT-358 
II.Nur77GFP.Thy1.1+ 6d effectors into PR8 infection-matched hosts with the OVAII/APC and 359 
analyzed them 14-16hr post transfer (Figure 5A). Only i.n. transfer of OVAII/APC induced 360 
Nur77GFP expression in donor effectors in the lung while i.s. transfer did not induce Nur77GFP 361 
expression over the negative control where APC without Ag (unpulsed APC) were transferred 362 
(Figure 5B). In concert with the site of Ag recognition as seen with Nur77GFP expression, 363 
OVAII/APC were found only in the lung with i.n. transfer and only in the spleen with i.s. transfer 364 
(Figure 5C). These results indicate that we achieved localization of APC and successfully 365 
restricted Ag presentation to the lung with i.n. transfer of Ag/APC and that i.s. transfer of Ag/APC 366 
serves as a control where Ag is not presented locally in the lung (Table 1).  367 
Table 1. Distribution of APC and Ag presenta-
tion in different sites using intranasal (i.n.), intra-
venous (i.v.) or intrasplenic (i.s.) transfer of APC.
Data summarized from Fig 5B-C, 5F-G, 6A, 6E
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We then analyzed ThCTL generation from the 6d effectors, 3 days after transfer, at 9 dpi. Both i.n. 368 
and i.s. Ag/APC transfer increased trafficking of total transferred effectors to the lung, compared 369 
to the negative control (Figure 5D). We compared ThCTL generation after i.n. vs i.s. Ag/APC 370 
delivery (Figure 5E). Strikingly, only i.n. delivery induced ThCTL. When we used i.s. delivery, 371 
few if any ThCTL were generated, suggesting that Ag in the lung is required for lung ThCTL 372 
generation.  373 
To test if peripheral Ag was sufficient to drive 6d effectors to ThCTL, we transferred OVAII/APC 374 
i.v. and compared ThCTL generation to i.n. OVAII/APC transfer. OT-II.Nur77
GFP.Thy1.1+ 6d 375 
effectors were also transferred into PR8 infection matched hosts (Figure 5A). 14-16hr after 376 
transfer, donor effectors in the lung expressed Nur77GFP when OVAII/APC were transferred either 377 
i.v. or i.n., indicating Ag recognition (Figure 5F). A greater proportion of donor effectors in the 378 
lung expressed Nur77GFP in hosts that received i.v. OVAII/APC compared to those that received 379 
i.n. OVAII/APC. However, transferred APC were found predominantly in the spleen with many 380 
fewer in the lung with i.v. APC transfer (Figure 5G). This is compatible with the hypothesis that 381 
after i.v. OVAII/APC transfer, donor effectors initially recognize Ag in the periphery before 382 
migrating to the lung (Table 383 
1).…………………………………………………………………………….                              384 
OVAII/APC transfer i.v., like i.s., increased trafficking of transferred effectors to the lung, 385 
compared to the negative control and even compared to i.n. OVAII/APC transfer (Figure 5H). 386 
These data (Figure 5D, Figure 5H) support the concept, that Ag presentation in the spleen enhances 387 
pathways that favor migration of T cells to the lung.  388 
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Development of donor ThCTL in the lung as measured by NKG2A/C/E expression (both percent 390 
and MFI) after i.v. transfer, was as low as the negative control (Figure 5I). CXCR6 and PD1 391 
expression by the NKG2A/C/E+ cells generated with i.v. OVAII/APC transfer was also lower 392 
compared to those generated with i.n. OVAII/APC (Figure S6A). This suggests that i.v. 393 
OVAII/APC did not optimally support full ThCTL differentiation even if 6d effectors recognize 394 
Ag initially in the SLO, before migrating to their site of residence in the lung. Thus, we suggest 395 
that peripheral Ag enhances migration of effectors to the lung, but ThCTL develop optimally only 396 
when Ag is presented in the tissue of residency, the lung. 397 
Delivery of Ag by different routes favors Ag presentation in distinct SLO during the effector 398 
phase and selectively drives DLN TFH or spleen TFH 399 
TFH, like ThCTL, are restricted to the SLO (DLN and spleen) and express signatures for residency 400 
in SLO (Fazilleau et al., 2009; Lee et al., 2015). We asked if DLN and spleen TFH required Ag 401 
presentation in their organ of residence to drive their development during the effector phase. Using 402 
the same approach for evaluating local Ag requirements as for ThCTL in Figure 5, we delivered 403 
Ag via OVAII/APC either i.n. or i.s. and transferred OT-II.Nur77
GFP.Thy1.1+ 6d effectors into PR8 404 
infection-matched hosts (Table 1). Transfer of OVAII/APC i.n. induced Nur77
GFP expression in the 405 
DLN and not in the spleen, while i.s. transfer induced Nur77GFP exclusively in donor cells 406 
recovered from the spleen and not in the DLN (Figure 6A). These results indicate that we had 407 
successfully restricted Ag presentation using i.n. vs i.s. delivery to the either the DLN or the spleen 408 
respectively (Table 1).  409 
We analyzed TFH generation from the 6d effectors, 3 days after transfer, at 9 dpi. The total number 410 
of donor cells recovered in the DLN, was increased following i.n. OVAII/APC transfer but not 411 
with i.s. OVAII/APC transfer and vice-versa for the number of donor cells recovered in the spleen 412 
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(Figure 6B). We found that TFH in the DLN developed from the 6d effectors, only when 413 
OVAII/APC were administered i.n. and not i.s. (Figure 6C). Conversely, spleen TFH were supported 414 
only when OVAII/APC were delivered i.s. and not when delivered i.n. (Figure 6D). Thus in the 415 
same experiment (Fig 5-6), TFH like ThCTL, develop only when Ag is presented in the tissue of 416 
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Fig. 6. DLN TFH and spleen TFH require local Ag presentation during the effector phase as 433 
shown by Ag delivery via i.n., i.s and i.v. routes (A) Experiment was performed as in Fig. 5A. 434 
Mice were harvested 14-16hr post-transfer (pt) and donor cell Nur77GFP expression was analyzed 435 
by flow cytometry in the DLN and spleen (i.n. vs i.s. APC). (B-D) Experiment was performed as 436 
in Fig. 5A and mice were harvested 3-4 dpt. (B) Total numbers of DLN and spleen donor effectors 437 
recovered with i.n. vs i.s. APC transfer (n=5-12 per group pooled,  3-4 independent experiments). 438 
(C) DLN donor TFH formation with i.n. vs i.s. APC transfer (n=5-10 per group pooled, 3 439 
independent experiments) (D) Spleen donor TFH formation with i.n. vs i.s. APC transfer (n=9-12 440 
per group pooled, 4 independent experiments). (E) Experiment was performed as in Fig. 5A. Mice 441 
were harvested 14-16hr post-transfer (pt) and donor cell Nur77GFP expression was analyzed by 442 
flow cytometry in the DLN and spleen (i.n. vs i.v. APC). (F-H) Experiment was performed as in 443 
Fig. 5A. Mice were harvested 3-4 dpt. (F) Numbers of donor effectors in the DLN and spleen when 444 
APC were transferred i.n. vs i.v. (n=5-11 per group pooled, 2-3 independent experiments). (G) 445 
Donor TFH formation in the DLN when APC were transferred i.n. vs i.v. (n=5-11 per group pooled, 446 
2-3 independent experiments). (H) Donor TFH formation in the spleen when APC were transferred 447 
i.n. vs i.v. (n=5-11 per group pooled, 2-3 independent experiments). Error bars represent s.e.m. 448 
Statistical significance determined by two-tailed, unpaired Student’s t-test (* P < 0.05, ** P < 0.01 449 
and *** P < 0.001). See also Fig. S6. 450 
 451 
We also tested if peripheral Ag was sufficient to drive 6 dpi effectors to TFH in the SLO. To do 452 
this, we transferred OVAII/APC i.v. with OT-II.Nur77
GFP.Thy1.1+ 6d effectors. After 14-16hr, 453 
donor effectors in both the spleen and DLN expressed Nur77GFP, indicating Ag recognition (Figure 454 
6E, Table 1) though APC were found predominantly in the spleen with i.v. APC transfer (Figure 455 
5G, Table 1). As seen for lung ThCTL, OVAII/APC transferred i.v. did not support donor DLN 456 
TFH generation but did support spleen TFH (Figure 6G-H, Figure S6B-C). This suggests that even 457 
if 6d effectors recognize Ag initially before migrating to their site of residence in the DLN, this is 458 
insufficient to induce development of DLN TFH. 459 
Altogether, these results support the concept that the final steps in full-fledged tissue-restricted 460 
ThCTL and TFH tissue-restricted effector generation from 6d effectors, require local Ag 461 
recognition in the site of residency. 462 
 463 
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DISCUSSION 464 
While the instrumental role of Ag during the priming of T cells is well appreciated, we show here 465 
that signals from local Ag and co-stimulation, during the effector phase, are required to drive 466 
development of specialized TFH and ThCTL tissue-restricted effectors. These results indicate that 467 
generation of these tissue-restricted effectors following influenza infection, unlike circulating Th1 468 
effectors, require that infection continues into the effector phase to supply these Ag signals. Thus, 469 
if infection is absent at this checkpoint, few of these specialized tissue effectors will develop.  470 
Given the well-studied roles of ThCTL in viral clearance and TFH in subsequent B cell Ab 471 
responses (Crotty, 2019; Juno et al., 2017; Marshall and Swain, 2011; McKinstry et al., 2012), the 472 
lack of these subsets will undermine a successful response. We postulate this checkpoint 473 
mechanism acts as a safeguard to limit TFH and ThCTL generation to those situations where there 474 
is an ongoing threat, thereby limiting unnecessary, potentially harmful responses. Indeed, 475 
exaggerated ThCTL and TFH responses are seen in certain autoimmune diseases and chronic 476 
infections (Broadley et al., 2017; Gensous et al., 2018) where continuous Ag and inflammation 477 
persist.  478 
Requirements for repeated/prolonged Ag for generation of TFH have been previously reported 479 
(Krishnaswamy et al., 2018), but this has been unexplored for other tissue-restricted CD4 effector 480 
subsets, such as ThCTL. It is known that TFH require repeated Ag recognition and costimulatory 481 
interactions during priming and at the T-B border and in the GC of the SLO (Krishnaswamy et al., 482 
2018). Thus, it is expected though unknown if TFH will require Ag recognition, well into the late 483 
effector phase as well. We show that this is indeed the case, but also show that the requirement of 484 
CD4 effectors for Ag recognition at the checkpoint is not restricted to TFH but part of a broader 485 
paradigm that drives multiple specialized CD4 responses, including TFH, ThCTL and CD4 486 
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memory. Importantly, we find that the cognate Ag requirement during the effector phase for both 487 
ThCTL and TFH can occur independently of both B cells and germinal centers. In addition, we 488 
show that CD4 effectors must recognize Ag in their tissue of residence to become tissue-restricted 489 
effectors.  490 
ThCTL are not found until after 6 dpi (Marshall et al., 2016) and the 6d effectors we transfer 491 
express no ThCTL markers (Figure S1E). Thus, we interpret their dependence on effector phase 492 
cognate-Ag recognition, as driving their generation from CD4 effectors. On the other hand, the 493 
TFH developmental program begins early during CD4 effector activation when effectors begin to 494 
express Bcl6 within the first few rounds of cell division (Vinuesa et al., 2016). Thus, the 6d 495 
effectors we transfer include some “pre-TFH” at 6 dpi (Figure S1D). The 6d pre-TFH have the 496 
potential to become TFH, but our data here (25-fold reduction to negligible TFH levels in the absence 497 
of Ag), suggest  they only realize that potential if they receive signals from Ag recognition again, 498 
locally, during the effector phase. We plan further studies to explore which of the programs – 499 
differentiation/generation, expansion, survival/maintenance - are induced by Ag recognition in this 500 
model.  Altogether, what is evident from our functional data is that, in the absence of Ag 501 
presentation during the effector phase, there are few if any TFH that drive GC responses (Figure 502 
2H-J) and few ThCTL that mediate MHC-II cytotoxicity (Figure 1E). 503 
During polyclonal responses, new naïve CD4 T cells are recruited throughout the response (Jelley-504 
Gibbs et al., 2005) and individual polyclonal cells have different propensities to become TFH 505 
because of their different TCRs (Krishnaswamy et al., 2018).These features create a non-506 
synchronized effector population which makes it difficult to identify cells at the same state of 507 
differentiation and track their fate. We circumvented these issues by generating effectors in situ 508 
from homogenous naïve TCR Tg CD4 T cells from two different models that gave corresponding 509 
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results: B6.OT-II and BALB/c.HNT. Moreover, we have reproduced the strict requirement for Ag 510 
recognition by CD4 effectors for memory generation in a BALB/c D0.11.10 model, in this B6.OT-511 
II model (Bautista et al., 2016; McKinstry et al., 2014) and in a new influenza NP-specific TcR 512 
Tg.  Usage of the TCR Tg sequential transfer model allowed the study of effector phase signals 513 
specifically, after 6 days post infection, which we could not have achieved using a polyclonal 514 
system. 515 
Our experiments here focus solely on the requirements at the effector phase from 6 dpi onwards, 516 
coincident with the previously defined checkpoint for effectors in memory studies (Bautista et al., 517 
2016; McKinstry et al., 2014). We identified several signals required to drive effectors at the 518 
checkpoint to TFH and ThCTL. First, effectors became TFH and ThCTL only when they recognized 519 
cognate Ag/APC at 6-8 dpi (Figure 1-2).  Previously, we showed that CD4 memory generation 520 
required cognate Ag recognition 6-8 dpi and that this was dependent on autocrine IL-2 induction 521 
(Bautista et al., 2016; McKinstry et al., 2014).  We confirmed the timeframe by blocking 522 
costimulatory pathways, blocking the IL-2 pathway and by adding back IL-2. The checkpoint 523 
coincides in situ with the peak of the effector response, which is followed by rapid contraction, 524 
supporting the concept that effectors express a default program of apoptosis which they avoid only 525 
when they recognize Ag (Bautista et al., 2016; McKinstry et al., 2014). We showed that the 526 
absence of effector checkpoint Ag results in poor CD4 memory development, corresponding with 527 
loss in protection against lethal influenza infection (Bautista et al., 2016). Thus, the development 528 
of three functionally specialized CD4 subsets, TFH, ThCTL and CD4 memory, each requires 529 
cognate Ag recognition during this effector checkpoint. In addition to TCR triggering by Ag, TFH 530 
but interestingly not ThCTL, required CD80/86 on the APC indicating distinct pathways are 531 
required for these distinct tissue-restricted effector subsets (Figure 3). 532 
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Second, we showed various activated MHC-II+ APC, including DC and B cells, drove donor 533 
effectors to develop into TFH and ThCTL (Figure 4) consistent with previous studies of APC 534 
subsets required during initial priming of TFH responses (Deenick et al., 2010; Deenick et al., 535 
2011). In our experiments, in vivo transferred DC present Ag for less than 48hr (Bautista et al., 536 
2016) indicating that effectors only need a brief period of TCR triggering. TFH were generated 537 
from 6d effectors even when Ag was presented only by DC (Figure 4F, Figure S5E) and even in 538 
the absence of B cells and GC in JhD 2nd hosts (Figure 4E, Figure S5D). Thus, although B cells 539 
may be the major source of Ag for TFH in situ, other MHC-II
+ APC are competent to drive TFH 540 
development at the effector phase. Given the critical importance of TFH to effective B cell 541 
immunity, this may allow development of strong TFH responses even if germinal center responses 542 
are impaired or Ag-specific B cells are limited. For instance, this may be a useful strategy for the 543 
immune system to be able to drive GC-independent B cell responses which benefit from TFH help, 544 
such as reactivation of previously generated memory B cells (Inoue et al., 2018).  545 
Third, the highest proportion and most well-differentiated TFH and ThCTL developed only when 546 
APC was delivered to the site of future residence (Figure 5-6). Recently, Ag presentation in tissues 547 
has been implicated in development of both T and B resident memory subsets (Allie et al., 2019; 548 
Khan et al., 2016; McMaster et al., 2018; Takamura et al., 2016). Our data suggest that local Ag 549 
presentation in the tissue site, establishes residency during the effector checkpoint. Previous 550 
studies have largely focused on tissue-resident T cell subsets in non-lymphoid tissues, however 551 
SLO also have distinct architecture and function (Lewis et al., 2019; Malhotra et al., 2013). Here 552 
we show that SLO-resident TFH subsets also have unique local Ag presentation requirements 553 
during the effector checkpoint (Figure 6) that are distinct from lung resident ThCTL and suggests 554 
that tissue-restricted Ag presentation is required even if they encountered Ag before entering the 555 
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local tissue niche (Figure 6E-H). A subset of SLO TRM has also been identified recently (Beura et 556 
al., 2018; Schenkel et al., 2014). Thus, our results here and those recent studies, solidify the 557 
previously underappreciated concept that SLO also harbor tissue resident T cell subsets with 558 
unique requirements for differentiation.  559 
 560 
The functional activity of TFH and ThCTL correlated well with the availability of the checkpoint 561 
signals. TFH required Ag recognition to produce IL-21 (Figure 2E) and to induce GCB (Figure 2H-562 
J). Likewise, the generation of ThCTL correlated with their cytotoxic function against target cells 563 
(Figure 1E). Tissue-restricted effector functions are critical to immunity (Devarajan et al., 2018). 564 
TFH drive GCB formation which leads to  B cell isotype class switching, generation of high affinity 565 
somatically mutated B cells, and generation of long-lived plasma cells and memory B cells (Crotty, 566 
2019). TFH are required for, and are a reliable indicator of, protective Ab after influenza vaccination 567 
(Koutsakos et al., 2019b). ThCTL reduce viral titers and are associated with better disease control 568 
in many viral infections (Juno et al., 2017; Muraro et al., 2017; Phetsouphanh et al., 2017) and 569 
tumor models (Melssen and Slingluff, 2017), especially those where class I is downregulated by 570 
viruses and tumor microenvironments where CD8 cytotoxic cells are ineffective. Tissue-restricted 571 
effectors are also likely the precursors of TRM which are at the frontline of immune defense to re-572 
infection. 573 
These results are directly relevant to vaccine design. The most common Ab viral epitopes on the 574 
surface proteins shift frequently, constraining the ability of long-lived Ab produced by B cells, to 575 
remain fully protective. Thus, T cells are central to broad immunity to influenza and other RNA 576 
viruses that mutate because the they target core proteins of viruses that rarely change (Devarajan 577 
et al., 2016). Our results suggest that vaccine approaches need to deliver Ag to tissues, such as 578 
Flumist which delivers Ag to the lung, if they are to efficiently drive the tissue-restricted CD4 T 579 
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cell subsets and CD4 memory. Additionally, unformulated soluble Ag/adjuvants in vaccines have 580 
been shown to be rapidly cleared from the body (Moyer et al., 2016), which may explain the low 581 
efficacy of current influenza vaccines in generating durable CD4 T cell responses and indirectly 582 
strong long-term B cell immunity. Several formulation strategies have been proposed such as 583 
synthetic polymer formulations, microneedle skin patches and polymer sponges to extend the 584 
kinetics of Ag presentation in vaccines (Moyer et al., 2016). One recent strategy engineered 585 
enhanced Ag binding on alum, which allowed Ag presentation well into the effector phase (Moyer 586 
et al., 2020) and elicited superior humoral immunity. We predict that such strategies are likely to 587 
better support tissue effector formation.  588 
Coupled with our earlier studies of memory generation (Bautista et al., 2016; McKinstry et al., 589 
2014), our results here support a new paradigm in which a set of critical fate decisions occur at the 590 
CD4 effector checkpoint to coordinately support generation of multiple alternate fates: CD4 591 
memory, TFH and ThCTL. We believe that the regulation of the response at the effector checkpoint 592 
by cognate Ag, can lend new perspective on mechanisms of autoimmune pathogenesis driven by 593 
CD4 tissue effectors. We also suggest that to induce durable immunity, the most effective vaccines 594 
must provide the effector checkpoint signals identified here at the right time and in the relevant 595 
sites, so as to drive robust tissue-restricted effector as well as memory cell generation resulting in 596 
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FIGURE LEGENDS 624 
Figure 1.  Cognate Ag during the effector checkpoint is required for lung ThCTL phenotype 625 
and function. (A) Experimental design for (B-D): Naïve OT-II.Thy1.1+ cells were transferred into 626 
PR8-OVAII infected mice (1
st hosts). At 6 dpi, OT-II.Thy1.1+ effectors were isolated from 1st hosts 627 
and transferred into following groups of 2nd hosts: 6 dpi PR8-OVAII-infected, 6 dpi PR8-infected, 628 
or uninfected mice. Donor cells were analyzed 8 dpi. (B) Percentage and numbers of donor lung 629 
ThCTL (NKG2A/C/E+) (n=19 per group pooled, 4 independent experiments). (C) Representative 630 
histogram of lung donor cell GzmB expression (negative control: naïve CD4 from uninfected 631 
mice). Normalized MFI of lung donor cell GzmB expression (n=10 per group pooled, 2 632 
independent experiments). (D) CD107a degranulation marker expression by lung donor cells (n=9 633 
per group pooled, 2 independent experiments). (E) Experimental design: In vivo 6d OT-II.Thy1.1+ 634 
effectors were transferred into 6 dpi PR8-OVAII or PR8 infection-matched TCRα/β
-/- mice. CFSElo 635 
target and bystander CFSEhi bystander cells were transferred at 7d. Representative CFSE 636 
histograms shown. Percentage Ag specific cytotoxicity in each group is shown. (F-G) Experiment 637 
done as in (E). Percentage of lung donor cells expressing intracellular IFNγ (F) and TNFα (G) (E-638 
G, n=7 per group pooled, 2 independent experiments).  Statistical significance determined by two-639 
tailed, unpaired Student’s t-test (* P<0.05, ** P<0.01, *** P<0.001). See also Figure S2. 640 
Figure 2. SLO TFH require Ag recognition during the effector checkpoint. Experiment 641 
performed as in Figure 1A for Figure 2A-G. (A) Percentage and numbers of spleen donor TFH 642 
(CXCR5+Bcl6+). (B) Number of spleen donor germinal center TFH (GL7
+CXCR5+Bcl6+). (C-D) 643 
Representative histogram of ICOS (C) and PD1 (D) expression by spleen donor cells (negative 644 
control: naïve CD4 from uninfected mice). Normalized ICOS MFI (C) and PD1 MFI (D) 645 
expression by spleen donor cells. (A-D, n= 10 per group pooled, 2 independent experiments). (E-646 
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G) Percentage of spleen donor cells expressing intracellular IL-21 (E), IFNg (F) and TNFa (G) 647 
(n= 9 per group pooled, 2 independent experiments). (H) Experimental design for (I-J): In vivo 648 
generated 6d OT-II.Thy1.1+ effectors were transferred into 2 dpi PR8-OVAII-infected or PR8-649 
infected mice. A group of 2 dpi PR8-OVAII-infected and PR8-infected mice, with no cells 650 
transferred, served as negative controls. Spleens from these mice were analyzed 4 dpt. (I) Number 651 
of host GCB cells (CD19+Fas+GL7+Bcl6+) formed. (J) Percentage and numbers of HA+ GCB. (H-652 
I, n=8-12 per group pooled, 2-3 independent experiments). Error bars represent s.e.m. Statistical 653 
significance determined by two-tailed, unpaired Student’s t-test (* P<0.05, ** P<0.01, *** 654 
P<0.001). See also Figure S3. 655 
Figure 3. TFH and ThCTL have different effector phase CD28 co-stimulation requirements. 656 
(A) Experimental design for (B, E-F): In vivo generated 6d OT-II.Thy1.1+ effectors were 657 
transferred into 6 dpi PR8-OVAII-infected WT or CD80/CD86
-/- mice. Spleen, DLN and lungs 658 
were harvested at 8 dpi. (B) Percentage and number of lung donor ThCTL (NKG2A/C/E+) (n=14-659 
19 per group pooled, 4 independent experiments). (C) Experimental design: In vivo generated 6d 660 
OT-II.Thy1.1+ effectors were isolated and stimulated with either anti-CD3 alone or anti-CD3 and 661 
anti-CD28 in vitro to mimic in vivo effector phase cognate Ag stimulation. (D) Ag specific 662 
cytotoxicity of donors generated as in Figure 3C, with anti-CD3 or anti-CD3 + anti-CD28 (Each 663 
E:T ratio is assayed in triplicate or single wells for +EGTA conditions, representative of 2 664 
independent experiments). (E-F) Experiment done as in Figure 3A. (E) Percentage and number of 665 
spleen donor TFH (n=14-19 per group pooled, 3-4 independent experiments). (F) Number of spleen 666 
donor GC-TFH (GL7
+CXCR5+ Bcl6+) (n=8-10 per group pooled, 2 independent experiments). 667 
Error bars represent s.e.m. Statistical significance determined by two-tailed, unpaired Student’s t-668 
test (* P<0.05, ** P<0.01 and *** P<0.001). See also Figure S4. 669 
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Figure 4. Multiple APC subsets are able to present cognate Ag during the effector phase to 670 
support TFH and ThCTL generation from 6d effectors. (A) Experimental design: In vivo 671 
generated 6d OT-II.Thy1.1+ or 6d HNT.Thy1.1+ effectors were transferred into PR8-OVAII 672 
infection-matched hosts (B-D), PR8 infection-matched hosts (E), or into PR8 infection-matched 673 
hosts together with OVAII/APC (F-G). Numbers of TFH (CXCR5
+Bcl6+) and ThCTL 674 
(NKG2A/C/E+) generated were enumerated by flow cytometry, 2-4 dpt in each of these models. 675 
(B) WT→ MHC-II KO (H2-Ab1−/−) bone marrow chimera mice that were made by transferring 676 
WT bone-marrow into MHC-II KO irradiated hosts, where MHC-II is restricted to the 677 
hematopoietic compartment, or into WT→WT bone marrow chimera control mice (n=7-8 per 678 
group pooled, 3 independent experiments). (C) MHC-II KO →B6 bone marrow chimera mice, 679 
where MHC-II is restricted to the non-hematopoietic compartment, or into WT→WT bone marrow 680 
chimera control mice (n=8-11 per group pooled, 3 independent experiments). (D) CD11cTg.H2-681 
Ab1-/- mice where MHC-II is restricted to CD11c+ cells or into CD4 KO control mice (n=7-11 per 682 
group pooled, 2-3 independent experiments). (E) JhD mice where B cells are absent or into WT 683 
control mice (n=8 per group pooled, 2 independent experiments). (F) WT mice with cognate Ag 684 
supplied via OVAII pulsed BMDC vs unpulsed BMDC controls (n=8-10 per group pooled, 3 685 
independent experiments). (G) WT mice with cognate Ag supplied via OVAII pulsed B cells vs 686 
unpulsed B cell controls (n=5-6 per group pooled 2 independent experiments). Error bars represent 687 
s.e.m. Statistical significance determined by two-tailed, unpaired Student’s t-test (* P<0.05, ** 688 
P<0.01 and *** P<0.001). See also Figure S5. 689 
Figure 5. Ag delivery via i.n., i.s and i.v. routes, during the effector phase, shows that local 690 
Ag presentation in the lung drives ThCTL generation from effectors. (A) Experimental design: 691 
OVAII peptide pulsed B-cells (CD45.1
+ or GFP+) were used as APC and transferred into PR8 692 
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infection-matched hosts 6 dpi either intranasally (i.n.), intrasplenically (i.s.) or intravenously (i.v.). 693 
Unpulsed APC were transferred both i.n. and i.s. (B-E) or  i.n. and i.v. (F-I) as negative controls. 694 
In vivo generated 6d OT-II.Nur77GFP.Thy1.1+ effectors were transferred i.v. Mice were harvested 695 
14-16hr post-transfer (pt) and donor cells were analyzed by flow cytometry. (B) Donor Nur77GFP 696 
expression (i.n. vs i.s. APC). (C) Number of transferred APC (i.n. vs i.s.)  (D-E) Experiment 697 
performed as in (A) and mice harvested 3-4 dpt. (D) Number of donor effectors recovered with 698 
i.n. vs i.s. APC transfer. (E) Lung donor ThCTL formation with i.n. vs i.s. APC transfer. (F-G) 699 
Experiment performed as in (A). Mice harvested 14-16hr post-transfer (pt) (F) Donor Nur77GFP 700 
expression (i.n. vs i.v. APC) (G) Number of transferred APCs (i.n. vs i.v.). (H-I) Experiment 701 
performed as in (A). Mice were harvested 3-4 dpt. (H) Number of lung donor effectors with i.n. 702 
vs i.v. APC. (I) Donor lung ThCTL formation with i.n. vs i.v. APC. (B-C, F-G: n=8-11 per group 703 
pooled, 3 independent experiments. D-E, H-I: n=5-12 per group pooled, 2-4 independent 704 
experiments) Error bars represent s.e.m. Statistical significance determined by two-tailed, unpaired 705 
Student’s t-test (* P < 0.05, ** P < 0.01 and *** P < 0.001). See also Fig S6. 706 
Figure 6. DLN TFH and spleen TFH require local Ag presentation during the effector phase 707 
as shown by Ag delivery via i.n., i.s and i.v. routes (A) Experiment was performed as in Figure 708 
5A. Mice were harvested 14-16hr post-transfer (pt) and donor cell Nur77GFP expression was 709 
analyzed by flow cytometry in the DLN and spleen (i.n. vs i.s. APC). (B-D) Experiment was 710 
performed as in Figure 5A and mice were harvested 3-4 dpt. (B) Total numbers of DLN and spleen 711 
donor effectors recovered with i.n. vs i.s. APC transfer (n=5-12 per group pooled,  3-4 independent 712 
experiments). (C) DLN donor TFH formation with i.n. vs i.s. APC transfer (n=5-10 per group 713 
pooled, 3 independent experiments) (D) Spleen donor TFH formation with i.n. vs i.s. APC transfer 714 
(n=9-12 per group pooled, 4 independent experiments). (E) Experiment was performed as in 715 
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Figure 5A. Mice were harvested 14-16hr post-transfer (pt) and donor cell Nur77GFP expression 716 
was analyzed by flow cytometry in the DLN and spleen (i.n. vs i.v. APC). (F-H) Experiment was 717 
performed as in Figure 5A. Mice were harvested 3-4 dpt. (F) Numbers of donor effectors in the 718 
DLN and spleen when APC were transferred i.n. vs i.v. (n=5-11 per group pooled, 2-3 independent 719 
experiments). (G) Donor TFH formation in the DLN when APC were transferred i.n. vs i.v. (n=5-720 
11 per group pooled, 2-3 independent experiments). (H) Donor TFH formation in the spleen when 721 
APC were transferred i.n. vs i.v. (n=5-11 per group pooled, 2-3 independent experiments). Error 722 
bars represent s.e.m. Statistical significance determined by two-tailed, unpaired Student’s t-test (* 723 













.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted September 3, 2020. . https://doi.org/10.1101/2020.09.03.281998doi: bioRxiv preprint 
      36 
 
MATERIALS AND METHODS 737 
Mice 738 
C57Bl/6 (B6), B6.CD45.1, B6.Thy1.1, B6.Nr4a1eGFP (Nur77GFP), B6.CD80/CD86 KO and 739 
B6.MHC II- were obtained from the Jackson Laboratory. B6.TCRα/β KO mice were obtained from 740 
Dr. Raymond Welsh (UMMS). Y-linked B6.OT-II mice were obtained from Linda Bradley (The 741 
Scripps Research Institute, La Jolla, CA) and were originally published by Frank Carbone’s group 742 
(Barnden et al., 1998) and were bred and maintained at the UMMS animal facility. BALB/c.HNT 743 
were obtained from David Lo (Scott et al., 1994) (The Scripps Research Institute, La Jolla, CA) 744 
originally and have been bred and maintained at the UMMS animal facility. Mice were at least 8 745 
weeks old prior to use.  746 
Virus stocks and infections 747 
Influenza A viruses (IAV) A/Puerto Rico/8/34 (PR8), originally from St. Jude Children’s Hospital, 748 
and A/PR8-OVAII, kindly provided by Dr. Peter Doherty, were grown and maintained at the 749 
Trudeau Institute. Mice were anesthetized with isoflurane (Piramal Healthcare) or with 750 
Ketamine/Xylazine (at a dose of 25/2.5mg/kg by i.p. injection) and were infected intranasally with 751 
influenza virus corresponding to a 0.2-0.3 LD50 dose of IAV in 50 uL of PBS. 752 
Bone marrow chimera mice generation 753 
Host mice for bone marrow chimeras were lethally irradiated with 2 doses of 570 rads, 3 hours 754 
apart. Bone marrow was isolated from the femurs and tibia of donor mice. The bone marrow was 755 
T cell depleted (using CD90.2 magnetic beads from Miltenyi) and adoptively transferred into 756 
lethally irradiated host mice by tail-vein i.v. injections. Bone marrow was transferred at a 1:1 or 757 
1:2 donor:host mice ratio. Mice were allowed to recover and reconstitute for at least 6 weeks prior 758 
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to use during which they were treated with antibiotics (0.63mg/ml Sulfadiazine and 0.13mg/mL 759 
Trimethoprim) added to their drinking water. Reconstitution was confirmed by flow cytometry of 760 
peripheral blood before use and again in all tissues harvested when the mice were used in 761 
experiments. 762 
In vivo day 6 effector generation and transfer/in vitro culture 763 
In vivo generated 6d CD4 T cell effectors were routinely obtained as described previously (Bautista 764 
et al., 2016). Briefly, cells from lymph nodes and spleens of naïve OT-II or HNT transgenic mice 765 
were enriched for naïve cells by percoll gradients and CD4 T cells isolated by CD4 positive 766 
selection (Miltenyi Biotec) or using a CD4 naïve positive selection kit (Miltenyi Biotec). Naïve 767 
CD4 T cells were adoptively transferred into mice (1st hosts), which were then infected with IAV 768 
(PR8 or PR8-OVAII). On day 6 post infection, the lung draining lymph nodes (DLN) and spleens 769 
were harvested and donor T cells were isolated using MACS (Miltenyi Biotec) based on their 770 
congenic marker (CD90.1). Immediately after isolation, the in vivo generated 1-2x106 6d CD4 771 
effectors were adoptively transferred intravenously (i.v.) into host mice (2nd hosts). 772 
In vivo generated 6d CD4 effectors were also cultured in vitro for 2 days by stimulating with plate 773 
bound anti-CD3 (2C11, 0.5ug/ml) or anti-CD3 and anti-CD28 (37.51, 20ug/mL) in T cell media 774 
(RPMI 1640 supplemented with 7.5% fetal bovine serum, 2mM L-glutamine, 50 uM 2-775 
mercaptoethanol, 100 IU penicillin, 100 ug/ml streptomycin and 10mM HEPES). 776 
In vitro APC culture and activation 777 
BMDC (bone marrow derived dendritic cells) (Bautista et al., 2016; Brahmakshatriya et al., 2017) 778 
and activated B cell (Bautista et al., 2016) generation was done as described previously. Briefly, 779 
bone marrow cells were flushed from femurs and tibia of mice and cultured in vitro with 10ng/mL 780 
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GMCSF (Biolegend). After 7 days, cells were harvested and enriched for dendritic cells with 781 
CD11c positive selection (Miltenyi Biotec). Dendritic cells were then matured with 10ug/mL Poly 782 
I:C (InVivoGen) overnight before use. Activated B cells were generated by isolating T depleted 783 
splenocytes using CD90.2 negative selection (Miltenyi Biotec) and culturing these in vitro for 2 784 
days with 10ng/mL LPS and 10ng/mL dextran sulfate. 785 
In vivo APC delivery 786 
To deliver Ag/APC (BMDC or activated B cells), APC were pulsed with 10μM OVA323–339 787 
(OVAII) peptide (New England Peptide) or no peptide as a negative control (unpulsed APC) for 1 788 
hour at 37oC with shaking. APC were washed and administered either intravenously (i.v.) in 200uL 789 
PBS, intranasally (i.n.) in 50uL PBS, or intrasplenically (i.s.) in 10uL PBS. 0.25-1x106 BMDC or 790 
1x106 B cells were transferred i.v., 0.5-2x106 BMDC or 1-2x106 B cells were transferred i.n. and 791 
0.5-1x106 B cells were transferred i.s. 792 
For intrasplenic transfer of APC, the animal was initially anaesthetized at 2.5%, then maintained 793 
at 1.5 – 1.75% isoflurane. Animal’s hair was clipped from the hip to mid chest on the animal’s left 794 
side. The area was sterilized and bupivacaine 1mg/kg was subcutaneously injected at the proposed 795 
incision site. Just below the last rib, using a pair of forceps, a 2 mm area of skin was held up and 796 
away from the body cavity and a 6-8mm incision was made by blunt dissection. PBS soaked cotton 797 
tipped applicators were used to lift the spleen out and hold in place. A 25µl Hamilton syringe with 798 
a 31-gauge Hamilton needle was used to inject the cells into the spleen. Sterile PBS was drawn 799 
into the syringe 3 times prior to the cells being drawn up. The syringe was held in a vertical position 800 
to the center of the spleen. The center of the top of spleen was penetrated by the needle at a depth 801 
of 2mm. The plunger was pushed slowly over a period of 10 seconds, and then the needle was left 802 
in the spleen for an additional 10 seconds. Using the cotton tipped applicators, the spleen was 803 
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placed back into the abdominal cavity. Muscle and skin layers were sutured closed. Upon 804 
completion of the surgery, meloxicam SR 4.0 mg/kg was administered subcutaneously over the 805 
right flank. 806 
T cell functional assays 807 
In vivo and in vitro cytotoxicity was performed as previously described (Marshall et al., 2016). 808 
Briefly, for in vivo cytotoxicity, T depleted splenocytes were stained with either 1uM or 0.4uM of 809 
CFSE denoting target (0.4uM) or bystander (1uM) cells. Target cells were pulsed with OVAII 810 
peptide for 1 hour at 37oC. Both populations were washed twice in PBS and adoptively transferred 811 
into host mice. 18 hours later, the spleens of host mice were harvested and the number of target 812 
and bystander cells were quantified by flow cytometry. Specific killing was calculated as: 100 x 813 
(1- (live targets/live bystanders)) normalized to the ratio found in control mice. For in vitro 814 
cytotoxicity, targets were activated B cells that were labeled as above using CellTrace Violet 815 
(Invitrogen). Effectors and targets were co-cultured in 96 U bottom plates in T cell medium at 816 
37oC 5% CO2 for 4 hours. Plates were washed and stained for cell viability using Annexin V and 817 
7-AAD (Invitrogen) or live/dead amine dyes (Invitrogen). Ag specific cytotoxicity was calculated 818 
as: 100 x (1- (live targets/live bystanders)) normalized to the ratio found in control wells with no 819 
effector cells. T cell degranulation and cytokine production was measured by ex vivo stimulation 820 
with plate bound 0.5ug/mL anti-CD3 and 20ug/mL anti-CD28 or with 10ng/mL PMA and 821 
500ng/mL Ionomycin for 4 hours at 37oC, 5% CO2 with brefeldin A (10ug/ml). T cell 822 
degranulation was also measured simultaneously with the addition of anti-CD107a PE (Biolegend, 823 
1:200), and monensin (BD GolgiStop, according to manufacturer’s protocol) at the beginning of 824 
the culture. Cells were harvested and stained for intracellular cytokines.  825 
 826 
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Flow cytometry 827 
Cells were harvested and passed through a 70uM nylon mesh, washed, and stained in FACS buffer 828 
[0.5% Bovine Serum Albumin, 0.01% sodium azide (Sigma-Aldrich) in PBS]. Cells were blocked 829 
with anti-FcR (2.4G2) and then stained with amine reactive viability dyes to exclude dead cells 830 
(Invitrogen). Surface antigens were stained with fluorochrome conjugated antibodies. Antibodies 831 
used: anti- CD4 (GK1.5), CD19 (6D5), CD44 (IM7), CD90.1 (OX-7 and HIS51), CD95 (Fas, Jo2), 832 
CD107a (1D4B), CD150 (SLAM, TC15-12F12.2), CD183 (CXCR3, CXCR3-173), CD185 833 
(CXCR5, SPRCL5), CD186 (CXCR6, SA051D1), CD278 (ICOS, C398.4A), CD279 (PD1, 834 
29F.1A12), CD335 (NKp46, 29A1.4), GL-7, IgD (11-26c), NK1.1 (PK136), and NKG2A/C/E 835 
(20d5). Binding to P-selectin was measured by incubating with P-selectin IgG Fusion protein (BD 836 
Bioscience), washed and detected with fluorochrome conjugated secondary goat anti-human 837 
antibodies (Jackson ImmunoResearch). HA reactivity was detected using HA conjugated to FITC. 838 
Following surface staining, cells were fixed with 2% paraformaldehyde (Sigma-Aldrich). For 839 
intracellular staining of cytokines, cells were first surface stained then fixed with 4% 840 
paraformaldehyde for 20 min, washed, and permeabilized with 0.1% saponin buffer (1% FBS, 841 
0.1%NaN3 and 0.1% saponin in PBS, (Sigma-Aldrich) for 15 mins. Subsequent staining for 842 
cytokines using the following antibodies: anti-IFNγ (XMG1.2), anti- TNFα (MP6-XT22). IL-21 843 
was detected using IL-21RFc (R&D systems), washed and detected with fluorochrome conjugated 844 
secondary goat anti-human antibodies (Jackson ImmunoResearch). GzmB was stained 845 
intracellulary directly ex vivo using anti-GzmB (GB11). For Bcl-6 staining, cells were first surface 846 
stained then fixed and permeabilized using the FoxP3 fix/perm kit (eBioscience) following 847 
manufacturer’s protocol and stained with anti-Bcl-6 (K112-91). Antibodies were obtained from 848 
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eBioscience, Biolegend, or BD Bioscience. Stained cells were acquired on an LSRII flow 849 
cytometer (BD) and analyzed using FlowJo analysis software. 850 
Statistics 851 
Unpaired, two-tailed, Students t-test was used to assess statistical significance between the means 852 
of two groups, with P < 0.05 considered significant. Analysis was done using Prism (Graphpad) 853 
software. Error bars in the figures represent the standard error of the mean. Significance in the 854 
figures are indicated as * P < 0.05, ** P < 0.01 and *** P < 0.001. Expression levels of different 855 
markers analyzed by flow cytometry are shown as MFI (Median Fluorescence Intensity) or nMFI 856 
(normalized MFI). To correct for batch effects while pooling data from different experiments, we 857 
normalized MFI by dividing each data point within an experiment by the average MFI of the 858 
control group from that experiment. nMFI = MFI/(average MFI of the control group) 859 
Study approval 860 
Experimental animal procedures were done in accordance with UMMS Animal Care and Use 861 
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